Objectives. The main aim was to analyse the long-term therapeutic effects on systemic sclerosis (SSc) patients of treatment with either (i) iloprost alone or (ii) low-dose oral cyclosporin A (CyA) associated with iloprost. A secondary aim was to analyse interleukin-6 (IL-6) serum levels in SSc patients before and after 1 yr of treatment.
Systemic sclerosis (SSc) is a chronic inflammatory dis-
CyA has been reported to improve both SSc skin ease characterized by fibrosis of the connective tissue, lesions [4] and oesophageal function [5] . Unfortunately, and involves skin, small vessels and internal organs [1] .
administration of Á3 mg/kg/day of CyA elicited Recently, clinical trials have been performed to evaluate concerns due to its renal toxicity [4] . the efficacy of immunosuppressive and vasodilator Questions remain unanswered concerning: (a) the drugs, since microvascular lesions and abnormalities of optimal CyA dosage in SSc, as lowering the CyA dosage the immune system have been recognized as being the may achieve a decrease in the incidence of side-effects most precocious alterations [2, 3] . In particular, the while maintaining the therapeutic effects; (b) the mecheffects of cyclosporin A (CyA) as an immunosuppressive anisms of CyA pharmacological action in SSc. agent, and iloprost, as a synthetic analogue of prostaRegarding the latter topic, CyA is known to affect glandin I 2 inducing preferential microvascular dilatation, the transcription of genes encoding several cytokines have been analysed.
[interleukin (IL)-2, IL-3, IL-4, IL-6, granulocytemacrophage colony-stimulating factor (GM-CSF ), tumour necrosis factor ( TNF )] [6-8], some of them involved in the pathogenesis of SSc [9] . In particular,
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IL-6 possesses fibrogenic and immunostimulatory effects [9] [10] [11] [12] . Thus, we determined IL-6 serum concentrations previous classifications, the NCV 'scleroderma patterns' before and after 12 months of therapy, considering the were divided into three groups, as follows: 'early', possibility that CyA could act in SSc by decreasing the 'active' and 'late' [20] . Change in shape (ramified capilproduction of this cytokine. laries), altered arrangement of the capillary loops The majority of clinical trials have evaluated only the (altered vascular architecture) and decrease in the short-term effects of iloprost on reduction of the severity number of capillaries were chosen as NCV parameters and frequency of Raynaud's phenomenon in SSc for the scoring of SSc patients. These measures show a patients [13] [14] [15] , while long-term trials have been conprogressive evolution during the natural course of the ducted on limited SSc series [16 ] . No accurate analysis disease. Furthermore, in our experience, the variability of the long-term outcome of iloprost treatment regarding index of such an NCV score is <10% when considering symptomatology, videocapillaroscopy pattern changes both the interassay variation (among tests repeated at and visceral organ involvement in SSc exists.
short time intervals) and the intra-assay variation We report the results of an open double-arm trial in (among measurements obtained by different operators which 20 SSc patients were randomized to receive treatat the same time). We adopted a semiquantitative rating ment with either iloprost alone or in association with scale assigning a score of '0' to the absence of NCV low-dose (2.5 mg/kg/day) long-term CyA. The tolerchanges and scores of '1', '2', '3' to minimal, intermediate ability and efficacy of both therapeutic regimens, and and maximal abnormal changes, respectively [20] . The the variations of IL-6 serum concentrations, in the two mean total NCV score for each subject was calculated groups of SSc patients are reported.
by summing the mean scores (obtained from all examined fingers; Table 1 ).
Patients, materials and methods
The oesophageal alterations were studied using manometry and 24 h pH-metry. A total oesophageal score Patients was created by summing the partial scores related to: Twenty consecutive patients (12-65 yr, 18 females and (i) the percentage of tertiary waves among the 24 h two males) affected by SSc were enrolled in the study at oesophageal waves; (ii) the pressure of the lower oesothe time of their first admission to the Department of phageal sphincter (LES) (mmHg); (iii) the percentage Internal Medicine. All patients fulfilled the ACR criteria of time with a pH of <4 during 24 h observation for classification of SSc [17] . Patients had been affected ( Table 1 ). In our experience, the consideration of all by diffuse (16 patients) or limited (four patients) forms these three parameters confers on the oesophageal score of SSc for no more than 2 yr. None were being adminisa high reproducibility index, although statistical data tered either steroid therapy or immunosuppressive drugs.
on the variability index are not available at the present All patients were affected by Raynaud's phenomenon.
time. However, it is known that pH-metry has elevated Consecutive patients were alternately randomized into reproducibility and very low variability [21] . Patients two groups which were matched for age, sex and disease stopped antacid and eukinetic treatments a week before pattern (constituted by eight patients with diffuse and commencement of the testing. two patients with limited SSc). Group I were adminisLung vital capacity ( VC ) and diffusive lung carbon tered monthly iloprost (1 ng/kg/min in 6 h i.v. infusion, monoxide (DLCO) were studied by spirometry. VC and for 5 consecutive days, 1 week per month), while Group DLCO spirometric scores were calculated. The sum of II received the same iloprost regimen as Group I as well both scores constituted the total lung score ( Table 1) . as oral CyA (2.5 mg/kg/day).
Flow resistance within small intrarenal vessels was The study was approved by the ethical committee of considered to be a major and highly sensitive index of the Department of Internal Medicine at the University sclerodermic kidney involvement, and was measured by of Genoa and all participants gave informed consent.
intrarenal duplex Doppler sonography [22] . The Resistive Index (RI ) was calculated in order to assess Clinical evaluation the renal intraparenchymal vascular bed. RI values of Complete clinical evaluations were performed before the ∏ 0.7 were considered normal [22] and scored as '0', beginning of treatment (baseline time or T0) and at the while RI values of >0.7 were considered abnormal and end of 12 months of therapy (end time or T12).
scored as '1' ( Table 1) . We utilized a battery of tests to evaluate cutaneous, Heart evaluation was performed using echocardiooesophageal, pulmonary, renal and cardiac functions, graphy, a procedure that allows the identification of left as well as the nailfold microvascular pattern. ventricular hypertrophy (LVH ) and/or pericardial In particular, cutaneous involvement was analysed by effusion (PE ). These conditions are frequent cardiac plicometry because this procedure seems to guarantee manifestations of SSc [23, 24] . better reproducibility and reduced variability than other skin scoring systems such as the 'Rodnan' score, as Sera recently described [18] . A total plicometer skin score Sera of the patients enrolled in the study were collected was assigned to each patient on the basis of the scores before the beginning of treatment and after 12 months obtained by measuring the plica of each skin area of therapy. The sera of 20 healthy, age-and sex-matched ( Table 1) . donors were also collected. All sera were stored at The small-vessel architecture was studied by nailfold videocapillaroscopy (NCV ) [19, 20] . In keeping with −80°C until analysis. Treatment  groupa  T0b  T12c  T0  T12  T0  T12  T0  T12  T0  T12   I 14.4 ± 2.1 12.3 ± 1.8d 4.8 ± 1.0 4.9 ± 0.9 5 ± 1.5 4.6 ± 1.2 1.5 ± 0.6 1.3 ± 0.3 0.1 ± 0.1 0.2 ± 0.1 (P = 0.1)e (P = 0.8) (P = 0.9) (P = 0.8) (P = 0.7) II 15.2 ± 2.0 11.3 ± 1.8 5.6 ± 2.2 3.8 ± 0.5 5.1 ± 1.7 4.3 ± 1.7 0.7 ± 0.3 0.5 ± 0.2 0.3 ± 0.1 0.3 ± 0.1 (P = 0.008) (P = 0.004) (P = 0.05) (P = 0.3) (P = 0.9) aGroup I, iloprost; Group II, iloprost + CyA. bBefore therapy. cAfter 12 months of therapy. dMean score ± .. eP level relative to the statistical difference between T0 and T12.
Determination of IL-6 concentrations trolled by decreasing the rate of i.v. infusion. No relevant CyA side-effects were seen in our series. In particular, Serum IL-6 concentrations were determined by the no signs of renal toxicity were detected. human Interleukin 6 ELISA kit from Endogen Inc.
No statistically significant differences were observed ( Woburn, MA, USA). The assay was performed in between the baseline and end time skin, NCV and duplicate and the results were expressed as pg/ml. The internal organ scores in Group I ( Table 2) . intra-assay and inter-assay coefficients of variations On the contrary, patients in Group II showed a were <10%.
significant reduction of skin (P = 0.008), NCV Statistical analysis (P = 0.004) and oesophageal scores (P = 0.05), but not of lung and renal scores, after 12 months of therapy The presence of statistically significant differences ( Table 2) . between means was analysed by the Mann-Whitney
The patients also self-reported subjective amelioration U-test for non-parametric values. All statistical evaluof their clinical status on a questionnaire in which any ations were performed using GraphPad InstatTM improvement of different disease symptoms and signs Version 2 and GraphPad PrismTM Version 2 software. was scored qualitatively (not shown). None of the patients in our series showed echocardioResults graphic alterations at baseline.
Clinical evaluation at baseline and after 12 months IL-6 serum levels in SSc patients and in healthy donors
The results reported in this study were collected before Baseline IL-6 serum levels were significantly higher in and after 12 months of therapy. All patients reported SSc patients than in healthy donors: 17.03 ± 17.9 and good tolerance to both therapeutic regimens, and no 17.5 ± 13.1 pg/ml in Group I and II, respectively, vs one withdrew from the study. The most frequent side-1.1 ± 1.5 in controls (P = 0.001). Baseline and end time effects observed during treatment with iloprost were headache, flushing and nausea which were well con-IL-6 serum concentrations in both Groups I and II were compared. A significant reduction of IL-6 serum conceninhibition of IL-6 production [36, 37] . The results of our study were consistent with this hypothesis since trations was observed after 12 months of treatment with the association of CyA and iloprost (3.8 ± 2.5 pg/ml, CyA treatment significantly decreased IL-6 serum concentrations while iloprost was unable to induce such P = 0.007), while no significant variations were detectable in patients treated with iloprost alone an effect.
In conclusion, the association of CyA and iloprost (12.3 ± 14.9 pg/ml, P = 0.3).
Since IL-6 is implicated in liver synthesis of acuteseems at the present time to be one of the most promising approaches to the long-term treatment of SSc. phase reactants, we measured the erythrocyte sedimentation rate ( ESR) and C-reactive protein (CRP) in the two groups at baseline and after 12 months of therapy. [35]. We hypothesized that therapeutic effects of CyA Iloprost infusion in patients with Raynaud phenomenon could be at least partially mediated by direct or indirect
